drugset / Trial / NCT06336018
A Research Study on Etavopivat in Participants With and Without Liver Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls). During the study, all participants will be given a single oral dose of etavopivat. All participants will take the etavopivat orally together with water. After dosing, the study will last for 7 to 9 days.
Timeline
- Start
- 2024-05-20
- Primary completion
- 2025-08-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etavopivat | Small molecule | — | Oral |